Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 848 across all filing types
Latest filing 2019-10-18 Regulatory Filings
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or fiscal period dates that would allow identification of a specific filing type. There is no indication of report titles, financial data, or announcements. Given the lack of discernible information, the document cannot be classified into any specific category and defaults to the fallback category for miscellaneous filings.
2019-10-18 English
FORM 4 -
Director's Dealing
2019-10-15 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 7, 2019, reporting a change in the company's independent registered public accounting firm from Grant Thornton LLP to Ernst & Young LLP. It details the dismissal of the previous auditor, the absence of disagreements or reportable events, and the engagement of the new auditor. The document includes a letter from the former auditor as an exhibit. This type of filing is a current report on material events and changes, specifically related to auditor changes, which is typically classified under Regulatory Filings (RNS) as it does not contain full financial statements or audit reports themselves but reports on changes and related disclosures. The document length and content confirm it is not an Annual Report, Audit Report, or other detailed financial report but a regulatory announcement of a change in auditor.
2019-10-09 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale under the Securities Act of 1933. It includes detailed information about the securities being registered, the selling stockholders, and the terms of the offering. The text references the registration of common stock shares issuable upon exercise of warrants, the Securities Purchase Agreement, and the registration fee calculation. This is a capital markets filing related to fundraising and securities registration, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual registration statement, not just an announcement of a report.
2019-10-07 English
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC by Ocugen, Inc. It amends a prior 8-K related to a merger transaction consummated on September 27, 2019. The amendment provides Ocugen's historical unaudited condensed consolidated financial statements as of June 30, 2019 and December 31, 2018, management's discussion and analysis (MD&A) for the same periods, and unaudited pro forma condensed combined financial statements. The document includes detailed financial data and MD&A, which are substantive financial disclosures. The filing is not merely an announcement or certification but contains actual financial statements and analysis. Given the nature of the filing as a current report amendment providing financial statements and MD&A related to a business acquisition, it fits best under the category of Regulatory Filings (RNS) because Form 8-K filings and amendments are generally classified as regulatory filings, and this document is not a full annual or interim report but an amendment to a current report with financial disclosures. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-10-07 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 4, 2019, by Ocugen, Inc. It details the issuance of warrants as part of a material definitive agreement related to a business combination and private placement financing. The content focuses on the terms and conditions of the warrants issued, including exercise prices, expiration, and other rights. There is no presentation of financial statements or comprehensive financial performance data. The document is a current report disclosing a material definitive agreement and financing activity, not an earnings release or annual/interim report. Therefore, it fits best under Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement of a report.
2019-10-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.